Prostaglandin E2 attenuates SR141716A-precipitated withdrawal in tetrahydrocannabinol-dependent mice
- 20 January 2003
- journal article
- Published by Elsevier in Brain Research
- Vol. 966 (1) , 47-53
- https://doi.org/10.1016/s0006-8993(02)04169-0
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Effects of the cannabinoid CB1 receptor antagonist, SR141716A, after Δ9-tetrahydrocannabinol withdrawalEuropean Journal of Pharmacology, 2000
- Abstinence symptoms following oral THC administration to humansPsychopharmacology, 1999
- Abstinence symptoms following smoked marijuana in humansPsychopharmacology, 1999
- Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with Δ‐9‐tetrahydrocannabinolBritish Journal of Pharmacology, 1998
- Receptor mediation in cannabinoid stimulated arachidonic acid mobilization and anandamide synthesisLife Sciences, 1997
- Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716AEuropean Journal of Pharmacology, 1995
- Prostanoid receptors of the EP3 subtype mediate the inhibitory effect of prostaglandin E2 on noradrenaline release in the mouse brain cortexNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1995
- Elevation of brain prostaglandin E2 levels in rodents by Δ1-tetrahydrocannabinolProstaglandins, Leukotrienes & Essential Fatty Acids, 1991
- Delta-9-tetrahydrocannabinol (THC) increases brain prostaglandins in the ratPsychopharmacology, 1985
- REGULATION OF NORADRENALINE OVERFLOW IN RAT CEREBRAL CORTEX BY PROSTAGLANDIN E2British Journal of Pharmacology, 1980